Presentations by Program

Discovery of ETX0462, a novel non-β-lactam PBP inhibitor to treat Gram-negative infections, including MDR Pseudomonas aeruginosa

Thomas Durand-Reville

In Vitro Activity of Sulbactam-Durlobactam against Recent Clinical Acinetobacter baumannii-calcoaceticus Complex Isolates

Sarah McLeod, Samir Moussa, Meredith Hackel and Alita Miller

ETX0462 is a Novel PBP Inhibitor with Potent Activity against Recent, Global, Gram-Negative Clinical Isolates

Sarah McLeod, Michael Huband, Jennifer Thompson, and Alita Miller

Evaluation of the Pharmacokinetics/pharmacodynamics (PK/PD) of the Novel Diazabicyclooctane(DBO) ETX0462 Against Pseudomonas aeruginosa Infections, Including MDR Strains

John O'Donnell, Angela Tanudra, April Chen, Dan Hines, Ruben Tommasi, Alita Miller, and Thomas Durand-Reville

The β-lactamase inhibitor ETX1317 restores the activity of cefpodoxime against recent (2017 2019), geographically diverse drug resistant Enterobacterales isolates

Sarah McLeod, Michael Huband, Jennifer Thompson, John Mueller and Alita Miller

Sulbactam-Durlobactam MIC and Disk Diffusion Quality Control Ranges Using A CLSI M23-A4 Study Design

Sarah McLeod, Nicole Carter and Alita Miller

The Novel, Non-β-lactam PBP Inhibitor, ETX0462, Has Potent Activity Against Biothreat Pathogens In Vitro and In Vivo

Ruben Tommasi, Henry Heine, George Drusano, Jason Cummings, Richard Slayden, Thomas Durand-Reville, John O’Donnell, and Alita Miller

Effect Of Susceptibility Testing Conditions On The In Vitro Antibacterial Activity Of Sulbactam-Durlobactam

Nicole Carter, Sarah McLeod and Alita Miller

ETX0462 Inhibits Penicillin-binding Protein 3 of Pseudomonas aeruginosa and Escherichia coli

Adam B. Shapiro, Sarah M. McLeod, Samir H. Moussa and Alita A. Miller

ETX0462, A Novel Non-β-lactam PBP Inhibitor, Is Bactericidal Against Gram-Negative Pathogens

Thomas Durand-Reville